查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830833

2025年性行为感染传染病分子诊断全球市场报告

Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，性行为感染感染分子诊断市场规模迅速扩张，从2024年的33.1亿美元成长至2025年的36.7亿美元，复合年增长率达10.9%。这段历史时期的成长可归因于性行为感染盛行率的上升、核酸增幅检查应用的增加、政府筛检措施带来的认知度的提升、全球卫生组织的支持以及诊断实验室的早期应用。

预计未来几年性行为感染分子诊断市场将快速成长，到2029年将达到54.8亿美元，复合年增长率为10.5%。预测期内的增长可归因于对早期疾病检测的日益重视、对个性化诊断的需求不断增长、性行为感染倡议的不断扩展、公私合营的不断加强以及对非侵入性检测方法的日益偏好。这段时期的主要趋势包括分子检测技术的进步、照护现场诊断设备的创新、基于多重PCR的检测组合的开发、携带式和自动化系统的进步，以及用于结果解读的人工智慧的整合。

性行为感染传染病 (STD) 的分子诊断技术透过检测传染源的遗传物质（DNA或RNA）来确认其存在。这些技术高度准确且灵敏，即使在无症状病例中也能检测到。透过分析病原体的分子结构，这些诊断方法能够进行明确鑑定，从而支持更快、更准确的诊断。

性传染病分子诊断的主要产品类型包括仪器和服务、耗材和软体。仪器包括用于病原体检测的诊断设备和平台，而服务则涵盖由医疗保健或诊断公司提供的实验室检测、样本处理和诊断结果解读。这些诊断技术采用多种技术，包括披衣菌感染检测和即时检测，用于各种应用，包括沙眼衣原体 (CT)、淋病奈瑟菌 (NG)、梅毒、淋病、单纯疱疹病毒 (HSV)、人类乳突病毒 (HPV)、人类免疫力缺乏病毒 (HIV)、滴虫、解脲支原体和霉浆菌的检测。

美国关税的快速上涨以及随之而来的2025年春季贸易摩擦，对医疗设备行业产生了重大影响，尤其对进口诊断影像设备零件、手术用不銹钢和塑胶耗材的影响。医院和诊所抵制涨价，挤压了製造商的净利率。监管障碍加剧了这个问题，因为与关税相关的供应商变更通常需要设备重新认证，从而延缓了产品上市时间。企业正在透过双重采购关键零件、扩大国内商品化生产以及加快高性价比材料的研发来降低风险。

本研究报告是商业研究公司（The Business Research Company）新报告系列的一部分，该系列提供性行为感染传染病分子诊断的市场统计数据，包括全球市场规模、各地区市场份额、性行为感染传染性行为感染分子诊断市场份额的竞争对手，以及详细的性行为感染感染分子诊断细分市场、市场趋势和商业机会，为您提供在性行为感染传播感染分子诊断行业取得成功所需的数据。这份性行为感染分子诊断市场研究报告透过对产业现状和未来情势的详细分析，为您提供全面的展望。

性行为感染感染 (STI) 盛行率的上升预计将推动性行为感染感染 (STI) 分子诊断市场的成长。 STI 是由细菌、病毒或寄生虫引起的感染疾病，透过性接触传播，影响生殖系统和泌尿器官系统。盛行率的上升主要是由于防护措施的使用不一致，这促进了性活跃人群之间的传播。分子诊断能够早期且准确地检测出病原体，包括无症状病例，从而及时治疗，遏制疾病传播，改善患者预后。例如，根据美国非营利组织 NACCHO（全国县市卫生官员协会）的数据，2024 年 1 月总合报告了 3,755 例先天性梅毒病例，比 2021 年到 2022 年增加了 31%。这种日益增长的盛行率正在推动性传染感染分子诊断市场的发展。

为了提高诊断的速度、准确性和可及性，该市场的主要企业正专注于快速即时聚合酵素链锁反应(PCR) 设备等创新。这些可携式设备将样品製备、扩增和检测集于一身，能够在传统实验室外进行高灵敏度的病原体检测。例如，2025 年 3 月，美国诊断科技公司 Visby Medical 推出了 Visby Medical 女性性健康检验。这种一次性手持式 PCR 设备无需外部设备或低温运输物流，即可在 30 分钟内从阴道样本中识别出披衣菌感染、淋病和滴虫。该测试获准凭处方笺在家中使用，是第一个获得 FDA 批准的可在临床环境之外使用的多种性传播感染的分子诊断测试，反映了分散化和可及性测试的趋势。

2024年12月，总部位于美国的照护现场和家用诊断解决方案提供商OraSure Technologies收购了Sherlock Biosciences。此次收购整合了Sherlock市售的披衣菌感染和淋病自检产品，扩大了OraSure在性健康领域的分子诊断产品组合。 Sherlock Biosciences专注于性行为感染传染病的分子诊断。

性行为感染分子诊断市场由提供检测开发、样本收集、核酸扩增和即时诊断等服务的供应商所获得的收益所构成。市场价值还包括服务提供者销售的或包含在其服务产品中的相关产品的价值。性行为感染分子诊断市场还包括聚合酵素链锁反应套件、恒温核酸增幅套件、基于成簇规律间隔短回文重复序列的检测以及无需仪器的分子诊断系统的销售。该市场的价值链是「工厂门口」价值，即产品製造商或创造者向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的产品价值。该市场中的产品价值还包括产品创造者销售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球性行为感染传染病分子诊断：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球性行为感染传染病分子诊断市场：成长率分析
  • 全球性行为感染传染病分子诊断市场表现：规模与成长，2019-2024
  • 全球性行为感染传染病分子诊断市场预测：规模与成长，2024-2029年，2034年
  • 全球性行为感染传染病分子诊断：总目标市场（TAM）

第六章 市场细分

  • 全球性行为感染传染病分子诊断市场：依产品、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 设备和服务
  • 耗材
  • 软体
  • 全球性行为感染传染病分子诊断市场：依技术、绩效与预测，2019-2024 年、2024-2029 年、2034 年
  • 实验室检查
  • 就地检验
  • 全球性行为感染传染病分子诊断市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 披衣菌感染披衣菌 (CT) 或淋病奈瑟菌 (NG) 检测
  • 梅毒检测
  • 淋病检查
  • 单纯疱疹病毒（HSV）检测
  • 人类乳突病毒（HPV）检测
  • 人类免疫力缺乏病毒（HIV）检测
  • 滴虫
  • 脲原体和霉浆菌
  • 其他用途
  • 全球性行为感染传染病分子诊断市场：依仪器及服务类型细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 分子诊断分析仪
  • 自动聚合酵素链锁反应系统
  • 核酸萃取装置
  • 诊断服务供应商
  • 维护和校准服务
  • 安装和培训服务
  • 全球性行为感染传染病分子诊断市场：依耗材（类型）细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 去氧核糖核酸萃取套件
  • 核糖核酸萃取试剂套件
  • 聚合酵素链锁反应试剂
  • 核酸探针
  • 标准和参考标准
  • 检测酵素和缓衝液
  • 全球性行为感染传染病分子诊断市场：依软体类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 数据解释和报告软体
  • 聚合酵素链锁反应工作流程管理软体
  • 实验室资讯管理系统
  • 诊断决策支援软体
  • 品管监控软体

第七章 区域和国家分析

  • 全球性行为感染传染病分子诊断市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球性行为感染传染病分子诊断市场：按国家/地区、绩效和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 性行为感染传染病分子诊断市场：竞争格局
  • 性行为感染传染病分子诊断市场：公司简介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Hologic Inc.
  • bioMerieux SA
  • QuidelOrtho Corporation
  • QIAGEN NV
  • Cepheid
  • Sansure Biotech Inc.
  • OraSure Technologies Inc.
  • Meridian Bioscience
  • Seegene Inc.
  • Visby Medical Inc.
  • Zeesan Biotech
  • Binx Health Inc.
  • GCC Biotech
  • GeneProof
  • Solone Life Sciences India（P）Ltd.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年性行为感染传染病分子诊断市场：提供新机会的国家
  • 2029年性行为感染传染病分子诊断市场：细分领域带来新机会
  • 2029年性行为感染传染病分子诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r37822

Molecular diagnostics for sexually transmitted diseases (STDs) involve methods that detect the genetic material, DNA or RNA of infectious agents to confirm the presence of pathogens. These techniques are highly accurate and sensitive, allowing detection even in asymptomatic cases. By analyzing the molecular structure of pathogens, these diagnostics ensure reliable identification, supporting faster and more precise diagnosis.

The primary product categories for molecular diagnostics of STDs include instruments and services, consumables, and software. Instruments comprise the diagnostic devices and platforms used for pathogen detection, while services cover laboratory testing, sample processing, and interpretation of diagnostic results provided by healthcare or diagnostic companies. These diagnostics employ various technologies, including laboratory-based testing and point-of-care testing, and are used in a range of applications such as testing for chlamydia trachomatis (CT), neisseria gonorrhoeae (NG), syphilis, gonorrhea, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV), trichomonas, ureaplasma, mycoplasma, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The molecular diagnostics for sexually transmitted diseases market research report is one of a series of new reports from The Business Research Company that provides molecular diagnostics for sexually transmitted diseases market statistics, including the molecular diagnostics for sexually transmitted diseases industry global market size, regional shares, competitors with the molecular diagnostics for sexually transmitted diseases market share, detailed molecular diagnostics for sexually transmitted diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the molecular diagnostics for sexually transmitted diseases industry. This molecular diagnostics for sexually transmitted diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular diagnostics for sexually transmitted diseases market size has grown rapidly in recent years. It will grow from $3.31 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth during the historic period can be credited to the rising prevalence of sexually transmitted infections, increased utilization of nucleic acid amplification tests, heightened awareness through government screening initiatives, backing from global health organizations, and early adoption by diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be ascribed to an increasing emphasis on early disease detection, rising demand for personalized diagnostics, expansion of sexually transmitted infection surveillance initiatives, growing public-private collaborations, and a greater preference for non-invasive testing approaches. Key trends during this period include advancements in molecular assay technologies, innovations in point-of-care diagnostic devices, development of multiplex PCR-based testing panels, progress in portable and automated systems, and the integration of artificial intelligence for result interpretation.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive growth in the molecular diagnostics for sexually transmitted diseases market. STIs are infections caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The increasing prevalence is largely attributed to inconsistent use of protection methods, which facilitates transmission among sexually active individuals. Molecular diagnostics enable early and accurate detection of pathogens, including in asymptomatic cases, allowing timely treatment, reducing disease spread, and improving patient outcomes. For example, according to the National Association of County and City Health Officials (NACCHO), a US-based nonprofit, a total of 3,755 congenital syphilis cases were reported in January 2024, representing a 31% increase between 2021 and 2022. This growing prevalence is therefore propelling the molecular diagnostics for STDs market.

Key companies in this market are focusing on innovations such as rapid point-of-care polymerase chain reaction (PCR) devices to enhance diagnostic speed, accuracy, and accessibility. These portable devices combine sample preparation, amplification, and detection in a single unit, enabling sensitive pathogen detection outside traditional labs. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women's Sexual Health Test. This single-use, handheld PCR device identifies chlamydia, gonorrhea, and trichomoniasis from vaginal samples in 30 minutes without external instrumentation or cold-chain logistics. Authorized for prescription home use, it represents the first FDA-cleared molecular diagnostic test for multiple STIs usable outside clinical settings, reflecting the trend toward decentralized, accessible testing.

In December 2024, OraSure Technologies, a US-based provider of point-of-care and home diagnostic solutions, acquired Sherlock Biosciences. This acquisition expanded OraSure's molecular diagnostics portfolio in sexual health by integrating Sherlock's over-the-counter chlamydia and gonorrhea self-test, which delivers lab-quality results in under 30 minutes using CRISPR- and isothermal amplification-based platforms. Sherlock Biosciences specializes in molecular diagnostics for sexually transmitted infections.

Major players in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMerieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular diagnostics for sexually transmitted diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The molecular diagnostics for sexually transmitted diseases market consists of revenues earned by entities by providing services such as test development, sample collection, nucleic acid amplification, and point of care diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular diagnostics for sexually transmitted diseases market also includes sales of polymerase chain reaction kits, isothermal nucleic acid amplification kits, clustered regularly interspaced short palindromic repeats-based tests, and instrument-free molecular diagnostic systems. values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on molecular diagnostics for sexually transmitted diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for molecular diagnostics for sexually transmitted diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The molecular diagnostics for sexually transmitted diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instruments And Services; Consumables; Software
  • 2) By Technology: Laboratory Testing; Point-Of-Care Testing
  • 3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing; Syphilis Testing; Gonorrhea Testing; Herpes Simplex Virus (HSV) Testing; Human Papillomavirus (HPV) Testing; Human Immunodeficiency Virus (HIV) Testing; Trichomonas; Ureaplasma And Mycoplasma; Other Applications
  • Subsegment:
  • 1) By Instruments And Services: Molecular Diagnostic Analyzers; Automated Polymerase Chain Reaction Systems; Nucleic Acid Extraction Instruments; Diagnostic Service Providers; Maintenance And Calibration Services; Installation And Training Services
  • 2) By Consumables: Deoxyribonucleic Acid Extraction Kits; Ribonucleic Acid Extraction Kits; Polymerase Chain Reaction Reagents; Nucleic Acid Probes; Control And Reference Standards; Detection Enzymes And Buffers
  • 3) By Software: Data Interpretation And Reporting Software; Polymerase Chain Reaction Workflow Management Software; Laboratory Information Management Systems; Diagnostic Decision Support Software; Quality Control Monitoring Software
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Hologic Inc.; bioMerieux S.A.; QuidelOrtho Corporation; QIAGEN N.V.; Cepheid; Sansure Biotech Inc.; OraSure Technologies Inc.; Meridian Bioscience; Seegene Inc.; Visby Medical Inc.; Zeesan Biotech; Binx Health Inc.; GCC Biotech; GeneProof; Solone Life Sciences India (P) Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Molecular Diagnostics For Sexually Transmitted Diseases Market Characteristics

3. Molecular Diagnostics For Sexually Transmitted Diseases Market Trends And Strategies

4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Molecular Diagnostics For Sexually Transmitted Diseases Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Growth Rate Analysis
  • 5.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Total Addressable Market (TAM)

6. Molecular Diagnostics For Sexually Transmitted Diseases Market Segmentation

  • 6.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments And Services
  • Consumables
  • Software
  • 6.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Testing
  • Point-Of-Care Testing
  • 6.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing
  • Syphilis Testing
  • Gonorrhea Testing
  • Herpes Simplex Virus (HSV) Testing
  • Human Papillomavirus (HPV) Testing
  • Human Immunodeficiency Virus (HIV) Testing
  • Trichomonas
  • Ureaplasma And Mycoplasma
  • Other Applications
  • 6.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Instruments And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Molecular Diagnostic Analyzers
  • Automated Polymerase Chain Reaction Systems
  • Nucleic Acid Extraction Instruments
  • Diagnostic Service Providers
  • Maintenance And Calibration Services
  • Installation And Training Services
  • 6.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Deoxyribonucleic Acid Extraction Kits
  • Ribonucleic Acid Extraction Kits
  • Polymerase Chain Reaction Reagents
  • Nucleic Acid Probes
  • Control And Reference Standards
  • Detection Enzymes And Buffers
  • 6.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Softwares, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Interpretation And Reporting Software
  • Polymerase Chain Reaction Workflow Management Software
  • Laboratory Information Management Systems
  • Diagnostic Decision Support Software
  • Quality Control Monitoring Software

7. Molecular Diagnostics For Sexually Transmitted Diseases Market Regional And Country Analysis

  • 7.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 8.1. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 9.1. China Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 9.2. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 10.1. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 11.1. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 11.2. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 12.1. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 13.1. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 14.1. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 14.2. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 15.1. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 15.2. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 16.1. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 17.1. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 18.1. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 19.1. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 20.1. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 21.1. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 21.2. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 22.1. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 23.1. North America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 23.2. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 24.1. USA Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 24.2. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 25.1. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 25.2. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 26.1. South America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 26.2. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 27.1. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 28.1. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 28.2. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 29.1. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 29.2. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape And Company Profiles

  • 30.1. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape
  • 30.2. Molecular Diagnostics For Sexually Transmitted Diseases Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Molecular Diagnostics For Sexually Transmitted Diseases Market Other Major And Innovative Companies

  • 31.1. Hologic Inc.
  • 31.2. bioMerieux S.A.
  • 31.3. QuidelOrtho Corporation
  • 31.4. QIAGEN N.V.
  • 31.5. Cepheid
  • 31.6. Sansure Biotech Inc.
  • 31.7. OraSure Technologies Inc.
  • 31.8. Meridian Bioscience
  • 31.9. Seegene Inc.
  • 31.10. Visby Medical Inc.
  • 31.11. Zeesan Biotech
  • 31.12. Binx Health Inc.
  • 31.13. GCC Biotech
  • 31.14. GeneProof
  • 31.15. Solone Life Sciences India (P) Ltd.

32. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Molecular Diagnostics For Sexually Transmitted Diseases Market

34. Recent Developments In The Molecular Diagnostics For Sexually Transmitted Diseases Market

35. Molecular Diagnostics For Sexually Transmitted Diseases Market High Potential Countries, Segments and Strategies

  • 35.1 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer